ABSTRACTS: 57, 58
Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations. Results from the studies were shared today in oral presentations at the 2023 American Society of Hematology (ASH) Annual Meeting. More information...
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development...
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas Advanced...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10 at the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park. The event brought together more than 400 leading scientists, including three Nobel laureates, from multiple disciplines to share groundbreaking immunotherapy and immunobiology research.
“Our inaugural symposium is an...
The University of Texas MD Anderson Cancer Center today announced the launch of its Institute for Data Science in Oncology (IDSO), which integrates...
The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration...
A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival...
The University of Texas MD Anderson Cancer Center and The University of Texas Health Science Center at Houston today announced Alejandro Aballay...
The University of Texas MD Anderson Cancer Center today broke ground on a 600,000-square-foot facility intended to anchor the institution’...
By improving hospital care pathways, researchers from The University of Texas MD Anderson Cancer Center successfully reduced inpatient opioid...
The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company...
Today The University of Texas System Board of Regents Chairman Kevin P. Eltife announced plans to launch a monumental healthcare initiative...
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe...
A new study led by researchers at The University of Texas MD Anderson Cancer Center provides a deeper understanding of the evolution of the...
The University of Texas MD Anderson Cancer Center and New Orleans-based Ochsner Health today announced a partnership to create Ochsner...
The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued...
ABSTRACTS: 3121, 4504, LBA4619
Three clinical trials led by researchers at The University of Texas MD Anderson Cancer Center demonstrated...
ABSTRACT: 4008
HER2-targeted bispecific antibody zanidatamab demonstrated durable responses in patients with treatment-refractory HER2...
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the appointment of its first members,...
Two researchers from The University of Texas MD Anderson Cancer Center have been elected to the prestigious National Academy of...
The University of Texas MD Anderson Cancer Center and Generate:Biomedicines today announced a strategic collaboration to jointly discover...
ABSTRACT: 3431
A new study led by researchers at The University of Texas MD Anderson Cancer Center discovered that co-occurring mutations...
The University of Texas MD Anderson Cancer Center applauds the National Cancer Institute’s (NCI) National Cancer Plan and its framework...
The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer...
The University of Texas MD Anderson Cancer Center and Xilis today announced a strategic collaboration to deploy Xilis’ proprietary MicroOrganoSphere...
The University of Texas MD Anderson Cancer Center and Replay today announced the launch of Syena, a new oncology-focused product company...
The University of Texas MD Anderson Cancer Center and Federation Bio today announced a strategic collaboration to design and manufacture a...
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson...